Recce的R327抗生素在早期测试中显示,在减少肺感染方面取得了显著成果。 Recce's R327 antibiotic showed strong results in reducing lung infections in early tests.

Recce制药公司报告说,其抗生素R327的临床预科结果大有希望,表明肺感染模式几乎完全减少了细菌感染,肺组织渗透率很高,有可能通过吸入直接交付。 Recce Pharmaceuticals reported promising preclinical results for its antibiotic R327, showing near-complete bacterial reduction in a lung infection model, with strong lung tissue penetration and potential for direct delivery via inhalation. Imugene Ltd在其第一阶段b试验中报告,总体答复率为82%;Azer-cel是用于复发或易碎扩散大型B细胞淋巴瘤的现成的CAR-T疗法,17名病人中有14人作了答复。 Imugene Ltd reported an 82% overall response rate in its Phase 1b trial of azer-cel, an off-the-shelf CAR-T therapy for relapsed or refractory diffuse large B-cell lymphoma, with 14 of 17 patients responding. 治疗以CD19为目标,旨在激活免疫系统抗癌。 The therapy targets CD19 and aims to activate the immune system against cancer. 与此同时,ASX面临暂时的系统故障,AUB集团在收购投标撤回后倒闭。 Meanwhile, the ASX faced a temporary system outage, and AUB Group fell after a takeover bid was withdrawn.